139 related articles for article (PubMed ID: 33473077)
1. [Cross-validation of Quantitative Analytical Software Using 18F-florbetapir PET Imaging].
Wagatsuma K; Miwa K; Sakata M; Ishibashi K; Ishii K
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2021; 77(1):32-40. PubMed ID: 33473077
[TBL] [Abstract][Full Text] [Related]
2. Decreased imaging time of amyloid PET using [
Wagatsuma K; Ishibashi K; Kameyama M; Sakata M; Miwa K; Kamitaka Y; Ishii K
Radiol Phys Technol; 2022 Jun; 15(2):116-124. PubMed ID: 35239129
[TBL] [Abstract][Full Text] [Related]
3. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal head-to-head comparison of
Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity.
Ali DG; Bahrani AA; Barber JM; El Khouli RH; Gold BT; Harp JP; Jiang Y; Wilcock DM; Jicha GA
J Alzheimers Dis; 2022; 88(3):1127-1135. PubMed ID: 35754276
[TBL] [Abstract][Full Text] [Related]
6. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.
Knešaurek K; Warnock G; Kostakoglu L; Burger C;
World J Nucl Med; 2018; 17(1):21-26. PubMed ID: 29398961
[TBL] [Abstract][Full Text] [Related]
8. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
10. Tracer-specific reference tissues selection improves detection of
Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
[TBL] [Abstract][Full Text] [Related]
11. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
12. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.
Tuszynski T; Rullmann M; Luthardt J; Butzke D; Tiepolt S; Gertz HJ; Hesse S; Seese A; Lobsien D; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1077-87. PubMed ID: 26739328
[TBL] [Abstract][Full Text] [Related]
14. Software development for quantitative analysis of brain amyloid PET.
Matsuda H; Yamao T
Brain Behav; 2022 Mar; 12(3):e2499. PubMed ID: 35134278
[TBL] [Abstract][Full Text] [Related]
15. Dual-phase
Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
[TBL] [Abstract][Full Text] [Related]
16. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
[TBL] [Abstract][Full Text] [Related]
17. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.
Jovalekic A; Roé-Vellvé N; Koglin N; Quintana ML; Nelson A; Diemling M; Lilja J; Gómez-González JP; Doré V; Bourgeat P; Whittington A; Gunn R; Stephens AW; Bullich S
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3276-3289. PubMed ID: 37300571
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of amyloid PET using
Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
[TBL] [Abstract][Full Text] [Related]
19. Quantification of 18F-florbetapir PET: comparison of two analysis methods.
Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD;
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
